Óscar Javier Cordero Santamaría-rekin lankidetzan egindako argitalpenak (11)

2022

  1. Evaluation of Blood Soluble CD26 as a Complementary Biomarker for Colorectal Cancer Screening Programs

    Cancers, Vol. 14, Núm. 19

2021

  1. Population-based universal screening for CRC: Secondary prevention

    Foundations of Colorectal Cancer (Elsevier), pp. 45-56

  2. The mechanism of sitagliptin inhibition of colorectal cancer cell lines' metastatic functionalities

    IUBMB Life, Vol. 73, Núm. 5, pp. 761-773

2020

  1. CD26-Related Serum Biomarkers: SCD26 Protein, DPP4 Activity, and Anti-CD26 Isotype Levels in a Colorectal Cancer-Screening Context

    Disease Markers, Vol. 2020

2019

  1. Surface expression marker profile in colon cancer cell lines and sphere-derived cells suggests complexity in CD26+ cancer stem cells subsets

    Biology Open, Vol. 8, Núm. 7

2015

  1. Characterization of the autoimmune response against the nerve tissue S100β in patients with type 1 diabetes

    Clinical and Experimental Immunology, Vol. 180, Núm. 2, pp. 207-217

  2. Serum dipeptidyl peptidase IV activity and sCD26 concentration in patients with choroidal nevus or uveal melanoma

    Clinica Chimica Acta

2014

  1. Postoperative serum levels of sCD26 for surveillance in colorectal cancer patients

    PLoS ONE, Vol. 9, Núm. 9

2010

  1. Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas

    BMC Cancer, Vol. 10

2009

  1. Soluble CD26 levels and its association to epidemiologic parameters in a sample population

    Disease Markers, Vol. 27, Núm. 6, pp. 311-316

2008

  1. How the measurements of a few serum markers can be combined to enhance their clinical values in the management of cancer

    Anticancer Research, Vol. 28, Núm. 4 C, pp. 2333-2341